{
    "nct_id": "NCT06307431",
    "official_title": "A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).",
    "inclusion_criteria": "* Has histologically or cytologically confirmed diagnosis of renal cell carcinoma (RCC) with clear cell or papillary histology.\n* Has intermediate-high-risk, high-risk, or M1 no evidence of disease (NED) RCC as defined by the following pathological tumor-node metastasis and tumor grading:\n* Intermediate-high-risk RCC: pT2 Gr4, N0, M0; pT3 Gr3/4, N0, M0\n* High-risk RCC: pT4, N0, M0; pT any stage, N1, M0\n* M1 NED RCC participants who present not only with the primary kidney tumor, but also solid, isolated, soft tissue metastases that can be completely resected at 1 of the following: the time of nephrectomy (synchronous), or ≤2 years from nephrectomy (metachronous)\n* Has undergone complete resection of the primary tumor (partial or radical nephrectomy) and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants.\n* Must have undergone a nephrectomy and/or metastasectomy ≤12 weeks prior to randomization and recovered from surgery and any post-operative complications before randomization.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has had a major surgery other than nephrectomy plus resection of preexisting metastases for M1 NED participants, within 4 weeks prior to randomization.\n* Has residual thrombus post nephrectomy in the vena renalis or vena cava.\n* Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Received prior treatment with a cancer vaccine.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has a history of brain or bone metastatic lesions.\n* Has severe hypersensitivity to study medication or any of the substances used to prepare the study medication.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years\n* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease\n* Has an active infection requiring systemic therapy\n* History of allogeneic tissue/solid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",
    "miscellaneous_criteria": ""
}